Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial Results

Go back to Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial Results
GALECTIN (NASDAQ: GALT) Delayed: 4.14 -0.47 (10.2%)
Previous Close $4.61    52 Week High $3.05 
Open $4.60    52 Week Low $0.49 
Day High $4.65    P/E N/A 
Day Low $4.10    EPS $-1.32 
Volume 392,939